Greg Giles has struggled with debilitating eczema for most of his life, relying on the injectable treatment Dupixent for relief. Nearly 20,000 Australians have turned to the medication since it was included in the Pharmaceutical Benefit Scheme in 2021, with its effectiveness and minimal side effects making it a popular choice. Despite concerns of being pulled from the PBS due to costs, a new deal has been secured to ensure continued access to the treatment, providing relief for patients and reducing healthcare expenses.
Full Article
Testosterone cream developed in WA revolutionises treatment for menopausal women but at treble the price
Androfeme, a testosterone cream developed in WA, offers a groundbreaking treatment for hypo-active sexual desire dysfunction, a common menopause side effect, but is not covered by the Pharmaceutical Benefits Scheme, costing $100 for a 100-day supply compared to $31.60 for men’s equivalents. Doctors advocate for its inclusion in the PBS to improve accessibility, as ongoing trials explore its effectiveness on additional menopause symptoms. Want More Context? 🔎
Read more